Amgen Inc logo

AMGN - Amgen Inc Share Price

$241.49 1.0  0.4%

Last Trade - 17/01/20

Sector
Healthcare
Size
Large Cap
Market Cap £109.29bn
Enterprise Value £116.12bn
Revenue £17.89bn
Position in Universe 65th / 6416
Bullish
Bearish
Unlock AMGN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AMGN Revenue Unlock AMGN Revenue

Net Income

AMGN Net Income Unlock AMGN Revenue

Normalised EPS

AMGN Normalised EPS Unlock AMGN Revenue

PE Ratio Range

AMGN PE Ratio Range Unlock AMGN Revenue

Dividend Yield Range

AMGN Dividend Yield Range Unlock AMGN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMGN EPS Forecasts Unlock AMGN Revenue
Profile Summary

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated October 31, 1986
Public Since May 1, 1987
No. of Shareholders: 5,760
No. of Employees: 21,500
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 594,183,541
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AMGN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AMGN
Upcoming Events for AMGN
Similar to AMGN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.